Stonepine Capital Management LLC Sells 45,000 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Stonepine Capital Management LLC lessened its stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 81.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 10,000 shares of the specialty pharmaceutical company's stock after selling 45,000 shares during the quarter. Jazz Pharmaceuticals makes up about 1.0% of Stonepine Capital Management LLC's holdings, making the stock its 25th largest position. Stonepine Capital Management LLC's holdings in Jazz Pharmaceuticals were worth $1,232,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently modified their holdings of the stock. Focus Partners Wealth bought a new stake in Jazz Pharmaceuticals during the fourth quarter worth $551,000. Moloney Securities Asset Management LLC bought a new stake in Jazz Pharmaceuticals during the fourth quarter worth $464,000. BTC Capital Management Inc. lifted its holdings in Jazz Pharmaceuticals by 9.4% during the fourth quarter. BTC Capital Management Inc. now owns 49,653 shares of the specialty pharmaceutical company's stock worth $6,115,000 after acquiring an additional 4,271 shares during the period. Summit Trail Advisors LLC bought a new stake in Jazz Pharmaceuticals during the fourth quarter worth $539,000. Finally, Atria Investments Inc lifted its holdings in Jazz Pharmaceuticals by 19.5% during the fourth quarter. Atria Investments Inc now owns 2,732 shares of the specialty pharmaceutical company's stock worth $336,000 after acquiring an additional 445 shares during the period. Institutional investors own 89.14% of the company's stock.

Insider Transactions at Jazz Pharmaceuticals

In other news, EVP Neena M. Patil sold 3,800 shares of the stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $144.87, for a total transaction of $550,506.00. Following the transaction, the executive vice president now directly owns 33,318 shares in the company, valued at approximately $4,826,778.66. This represents a 10.24% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CAO Patricia Carr sold 4,813 shares of the stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $144.42, for a total value of $695,093.46. Following the transaction, the chief accounting officer now owns 8,237 shares in the company, valued at $1,189,587.54. This trade represents a 36.88% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 28,236 shares of company stock valued at $3,956,190. 4.20% of the stock is owned by corporate insiders.

Jazz Pharmaceuticals Stock Performance

Shares of NASDAQ JAZZ traded down $2.75 during mid-day trading on Wednesday, hitting $108.27. The company had a trading volume of 1,054,687 shares, compared to its average volume of 850,969. The company has a market capitalization of $6.67 billion, a price-to-earnings ratio of 15.25, a P/E/G ratio of 1.04 and a beta of 0.38. Jazz Pharmaceuticals plc has a 1 year low of $95.49 and a 1 year high of $148.06. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46. The stock's 50-day moving average price is $114.15 and its 200-day moving average price is $121.92.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last posted its earnings results on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 EPS for the quarter, missing the consensus estimate of $4.65 by ($2.97). The business had revenue of $897.84 million for the quarter, compared to analysts' expectations of $984.16 million. Jazz Pharmaceuticals had a return on equity of 29.30% and a net margin of 11.60%. Jazz Pharmaceuticals's quarterly revenue was down .5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.68 earnings per share. On average, sell-side analysts forecast that Jazz Pharmaceuticals plc will post 16.96 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages recently commented on JAZZ. Cantor Fitzgerald lowered Jazz Pharmaceuticals from an "overweight" rating to a "neutral" rating and lifted their price target for the stock from $140.00 to $150.00 in a report on Wednesday, February 26th. Royal Bank of Canada lowered their target price on Jazz Pharmaceuticals from $182.00 to $172.00 and set an "outperform" rating on the stock in a research note on Wednesday, May 7th. Morgan Stanley dropped their price target on Jazz Pharmaceuticals from $183.00 to $166.00 and set an "overweight" rating on the stock in a research report on Wednesday, May 7th. Robert W. Baird decreased their price objective on Jazz Pharmaceuticals from $167.00 to $155.00 and set an "outperform" rating for the company in a report on Wednesday, May 7th. Finally, UBS Group raised shares of Jazz Pharmaceuticals from a "neutral" rating to a "buy" rating and upped their price objective for the company from $145.00 to $179.00 in a report on Friday, March 7th. Two research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $182.79.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.